Companies
Monte Rosa to receive $50 million as Novartis starts Sjögren’s Phase 2 study
Novartis is running the MRT-6160 trial under an exclusive worldwide license, with the first patient visit triggering a payment to Monte Rosa.
Search stocks, ETFs and companies
Universal file
SEC-verified company · Nasdaq · GLUE
Monte Rosa Therapeutics, Inc.
Verified identity
Start with the filing record
The identity and ticker come from the SEC’s official company ticker mapping. Market and editorial coverage are not inferred from that record.
- Ticker
- GLUE
- CIK
- 0001826457
- Exchange
- Nasdaq
- Universe updated
- 2026-08-22
Market price
Market price
Latest quoteOpens Google
TickerGrove coverage
Latest on Monte Rosa Therapeutics, Inc.
Research foundation
Read the filing with the right frame
Company analysis
Revenue, EPS and guidance answer different earnings questions
Revenue is the top-line amount recognized from a company’s activities under its accounting policy.
Company analysis
The three financial statements describe one business from different angles
The income statement records revenue and expenses over a period.
Investing basics
Stocks, ETFs and indexes are different objects
A stock is an ownership interest in one company.